The kinase PfCLK3 plays a critical role in the regulation of malarial parasite RNA splicing and is essential for the survival of blood stage Plasmodium falciparum. We recently validated
Introduction
In the global fight against malaria the distribution of over 0.5 billon insecticide impregnated bed nets since 2015, together with artemisinin-based combination therapies have contributed to 20 million few cases of malaria being reported in 2017 compared to 2010. 1 Despite this success, the rate of reduction in malaria has flattened with no significant reduction seen over the last 3 years. 1 This, together with evidence of the emergence of resistance to both artemisinin 2,3 and partner drugs including piperaquine and mefloquine 4, 5 means that there is a danger that the progress made in the reduction of malaria over the last several years will be reversed unless new medicines with novel mechanisms of action are discovered. To this end we have been testing the notion that targeting malaria parasite protein kinases might offer a novel strategy for the development of next generation antimalarials. 6, 7 In 2011 we determined that 36 or the 65 eukaryotic protein kinases are essential for the survival of the blood stage of the most virulent species of human malaria, Plasmodium falciparum. 8 Among these protein kinases was PfCLK3 (PF3D7_1114700), one of four members of the cyclin-dependent like protein kinase family (PfCLK1-4). The plasmodium CLK-family are closely related to the mammalian CLK family and the serine-arginine-rich protein kinase (SRPK) family 9 both of which are crucial mediators of multiple phosphorylation events on splicing factors necessary for the correct assembly and catalytic activity of spliceosomes. 10 Our in vitro studies showing that PfCLK3 can phosphorylate parasite SR proteins 11 indicates that PfCLK3, together with other members of the PfCLK family 12 , plays a role in the processing of parasite RNA. 9 We reasoned therefore that inhibitors to PfCLK3 might have parasiticidal activity at any stage of the parasite life cycle where RNA splicing played an essential role.
Screening of ~25,000 compounds including all 13,533 compounds of the Tres Cantos Antimalarial Set (TCAMS) resulted in the discovery of TCMDC-135051 (1, Figure 1 ), a compound with nM activity against PfCLK3 in in vitro kinase assays and sub µM parasiticidal activity in blood stage P. falciparum (Figure 1 ). 13 Subsequent studies revealed that TCMDC-135051 rapidly killed P. falciparum at the trophozoite to schizont stages as well as preventing the development of stage V gametocytes and inhibition the development of liver stage parasites. Our recent studies have therefore validated PfCLK3 as a target with the potential to deliver a curative treatment, be transmission blocking and act as a prophylactic target. 7-Azaindoles are a widely studied pharmacophore incorporated in several therapeutic agents. 14 Kinases are the predominate target with the 7-azaindole moiety generally interacting at the ATP binding site within the kinase hinge region. 15, 16 Interaction occurs between the kinase hinge region peptide backbone and the azaindole via two H-bonds. The first involving the pyridine nitrogen lone pair and peptide backbone NH, and the second between the pyrrole NH and peptide backbone carbonyl. The resulting H-bond acceptor and donor bidentate 7-azaindole interaction with the hinge region of the kinase can occur in the more common "normal" orientation or the "flipped" orientation with the 2-position of the 7-azaindole projected out of the hinge region into the solvent exposed space.. 17, 18 A number of small molecule kinase inhibitors have progressed to different stages of clinical trials. 19 Potential drug candidate GSK1070916 is being developed as an Aurora kinase (Ser/Thr protein kinases family) inhibitor and has reached human clinical trials (Figure 2A ). 20 The core scaffold is a 7-azaindole with aromatic substituents in the 2-and 4-positions. A Xray crystal structure with the molecule bound revealed a flipped hinge region binding mechanism, with 2-aryl projecting out of the hinge region into solvent and 4-aryl bound within the ribose pocket. Substructure analysis using Scifinder revealed several 7-azaindole analogues described as antimalarials. In 1972, Verbiscar et al. reported the first example of a 7-azaindole with antimalarial activity. 21 1-p-Chlorobenzyl-7-azaindole-3-α-piperidylmethanol displayed antimalarial activity in mice against Plasmodium berghei ( Figure 2B ). More recently, Picard et al. reported 7-azaindole compounds that were identified from an in silico structure-based drug screen (10,13,483 compounds, Chembridge). 22 Compound IND31119 ( Figure 2C In addition to antimalarial activity, the 7-azaindole scaffold has been identified as having a wide variety of biological applications including antitumor activity and for the reduction of antiviral activity in HIV-1-Infected patients. 23, 24 The 7-azaindole motif can be regarded as a privileged scaffold in medicinal chemistry as it is found in three clinical candidates (Vemurafenib, PLX3397, and AZD5363) ( Figure 2C ), which suggests its usefulness for developing novel pharmaceuticals. [25] [26] [27] To investigate the structure-activity relationship of hit compound 1 a series of analogues were prepared through varying different substituents on ring-A and ring-B ( Figure 1 ). The Ndiethyl amine group (ring A) was initially replaced with different amine substituents to investigate lipophilicity and solubility (Figure 1, SAR1 ). Next, we replaced the methoxy moiety (ring A) with hydroxyl or hydrogen to improve polarity and to explore the role of the with other substituents to investigate the role in binding, potentially improve metabolic stability and to explore the effect of increase lipophilic character (Figure 1, SAR4 ).
TCMDC-135051 is a promising hit compound for a medicinal chemistry programme to develop as a preclinical lead that meets many of the criteria set by the Medicines for Malaria Venture (capable of rapidly clearing the parasite, multi-stage, parasite killing across multiple species with action as a transmission blocker). 28, 29 Here we describe the synthetic route to TCMDC-135051 and determine a structure-activity-relationship that resulted in an improvement in in vitro and in vivo potency together with improved drug-like properties.
Chemistry
To investigate the effect of the N-diethyl group of ring-A on antimalarial activity, analogues Compound 9 was prepared as described in Scheme 1. The carboxylic acid of 1 was converted to its corresponding ethyl ester by refluxing in thionyl chloride and ethanol for 18h. To investigate the precise role of the methoxy group of ring-A on activity, we prepared analogues 21 and 25 in which the OMe is replaced by a hydroxy group (21) To investigate whether the substitution pattern on ring A is important for antimalarial activity, we produced analogue 29 in which the methoxy group is moved from the ortho to para position relative to the methylene N-diethyl functionality (Scheme 3). An isomer in which the isopropyl and carboxylic acid were switched, 34 was synthesized to investigate the role of these functional groups on antimalarial activity (Scheme 4). 
Result and discussion
In this work, we have maintained the core 7-azaindole molecular scaffold of TCMDC-135051 and focused on the structure−activity relationships (SARs) of the substitutes on ring-A and -B. All synthesised analogues were assessed in a TR-FRET assay against the full recombinant protein kinase PfCLK3 (Table 1 and Table 2 ). Analogues which gave low nanomolar activity were then further assessed in parasites 3D7 (chloroquine sensitive) strains of P. falciparum (Table 1 and Table 2 ). (Table 1) . Surprisingly when tested in parasites, 8b IC 50 = 446.3 nM (pIC 50 = 6.4) shows a slight decrease in parasiticidal activity whereas analogue 8c IC 50 = 2032 nM (pIC 50 = 5.7) shows a 10-fold decrease in parasiticidal activity (Table 1) . To increase the solubility of the hit molecule we replaced the N-diethyl functionality with a primary amine, 13. The substitution was detrimental for the potency of the hit molecule. Analogue 13 incorporating a primary amine gave IC 50 = 75.5 nM (pIC 50 = 7.1), was 3-fold less potent in vitro and showed dramatic loss of efficacy IC 50 = 3445 nM (pIC 50 = 5.5) in parasites indicating the need to sterically block the amine group for activity (Table 1 ). Analogue 16 IC 50 = 79.0 nM (pIC 50 = 7.1) was less potent in vitro and in parasites IC 50 = 1207 nM (pIC 50 = 5.9). There was a 6-fold drop in the activity, suggesting that the methylene linking the N-diethyl group to ring A is important for antimalarial activity (Table 1) . To explore the importance of the methoxy group (OMe) on ring-A, two analogues 21 and 25
were prepared and examined for in vitro antimalarial activity. We first replaced the OMe group with a hydroxyl to investigate the role of polarity on activity. Next, we replaced the OMe group with hydrogen (25) to investigate the importance of this functionality for activity. For both compounds 21 IC 50 = 21.56 nM (pIC 50 = 7.7) and 25 IC 50 = 24.78 nM (pIC 50 = 7.6) in vitro potency was retained (Table 1) Table 2) . Therefore this group is not required for binding in vitro, however the effect of lipophilicity is very important for parasiticidal activity.
At this point we decided to increase the lipophilicity and replace the isopropyl group to the larger tert-butyl group. However due to restriction of chemistry of boronate esters (instability of tert-butyl anion required for S N Ar reaction; see SI for boronate ester synthesis)
we could not synthesize the proposed molecule. From these data, the alkyl substituent on ring-B appears not to be involved in the recognition event with PfCLK3, however is key in terms of overall molecular lipophilicity for parasiticidal activity.
To investigate the requirements (ie. ionic and H-bonding) of the carboxylic acid (ring B) for antimalarial activity we employed a series of structural changes. The presence of a carboxylic acid functionality in a drug molecule has several potential drawbacks including limited permeability across biological membranes, metabolic instability, and potential idiosyncratic toxicities. A common isostere of a carboxylic acid, that overcomes many of these physicochemical limitations, is a tetrazole. We therefore designed tetrazole analogue,
32.
This change was orchestrated to increase lipophilicity of the molecule, retain H-bonding capability and investigate the role of potential ionic interactions with the enzyme.
Tetrazole analogue 32 shows comparable potency with TCMDC-135051 IC 50 = 18.5 nM (pIC 50 = 7.7) in vitro, as well as in IC 50 = 271.3 nM (pIC 50 = 6.6) parasites ( Table 2 ). This may be because 32 has improved lipophilicity and resulted in efficient penetration of parasite infected erythrocytes. Analogue 33 IC 50 = 1.03 µM (pIC 50 = 6.0) was completely inactive in vitro and demonstrates the importance of the carboxylic acid group (Table 2 ). Table 2 ).
The final part of our SAR assessment was dedicated to exploring the possibility of orientation of key substituents. Varying the position of the OMe group from para to the ortho-position 29 IC 50 = 17.47 nM (pIC 50 = 7.9) had retained activity in vitro. Whereas when 29 IC 50 = 3167 nM (pIC 50 = 7.5) was tested in parasites activity was lowered by 15-fold magnitude ( Table 1 ). The observed loss of potency in parasites may be due to the steric clash/spatial interaction of OMe with NEt 2 group resulting in loss of lipophilicity imparted by ethyl groups.
We next investigated the position of the isopropyl and carboxylic acid substituents of ring B
34 on antimalarial activity. The change of orientation of the substituent is detrimental for the activity in vitro IC 50 = 13,850 nM (pIC 50 = 7.9) as well as in parasites IC 50 = ND ( Table 2 ).
This data suggested that the positioning of the isopropyl and carboxylic acid group was essential for binding to its cellular target.
No X-ray crystal structure has been reported for PfCLK3 and so a homology model of PfCLK3 was created using the structure of human PRPF4B kinase domain as the closest homologue (PDB 6CNH). Overlay with Human Jnk1alpha kinase with 4-phenyl-7-azaindole IKK2 inhibitor bound (PDB 4AWI) facilitated identification of the proposed binding pocket. Based on this model we propose that the 7-aza-indole scaffold interacts with the hinge region in the flipped conformation H-bonding to the peptide backbone of the hinge region. The benzoic acid on Ring B occupies the ribose pocket and the Ring A diethyl-amine occupies the solvent exposed space.
Conclusions
In summary, we report the synthesis of hit PfCLK inhibitor TCMDC-135051 1 (PfCLK3 IC 50 
